A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates

Clinical Pharmacokinetics

Volumn 50, Issue 8, 2011, Pages 493-503

  Traunmller, Friederike ^a   Popovic, Martin ^a,b   Konz, Karl Heinz ^c   Vavken, Patrick ^d,e   Leithner, Andreas ^f   Joukhadar, Christian ^a,e,g  

^a JandP Medical Research Ltd   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Antibacterials; Children; Dose prediction; Fosfomycin; Neonates; Pharmacodynamic modelling; Pharmacokinetic pharmacodynamic relationships; Pharmacokinetic modelling

Indexed keywords

FOSFOCINE; FOSFOMYCIN; INFECTOFOS; SANDOZ; SOLUFOS; UNCLASSIFIED DRUG;

AGE; ANTIBIOTIC THERAPY; BODY WEIGHT; BOLUS INJECTION; CHRONOTHERAPY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; HUMAN; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NEWBORN CARE; NEWBORN INFECTION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PREMATURITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STEADY STATE;

AGE FACTORS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 79960198436     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11592670-000000000-00000     Document Type: Review

References (51)

1. Klevens RM, Morrisson MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298 (15): 1763-71. (Pubitemid 47598444)
2. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumo- niae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010 Sep; 36 (3): 197-204.
3. Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfo- mycin (phosphonomycin). Ann N Y Acad Sci 1974; 235: 364-86.
4. Popovic M, Steinort D, Pillai S, et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29: 127-42.
5. Sandoz GmbH. Fosfomycin "Sandoz" 1g i.v.-Trockensubstanz zur In- fusionsbereitung: summary of product characteristics [in German; online]. Available from URL: http://www.pharmazie.com/graphic/A/07/0-17307.pdf [Accessed 2011 May 5].
6. Daza R, Gutierrez J, Piedrola G, et al. Antibiotic susceptibility of bacterial strain isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-5. (Pubitemid 32979192)
7. Bert F, Bruneau B, Lambert-Zechovsky N, et al. Epidemiological studies ofthe susceptibility of Pseudomonas aeruginosa to antibiotics [in French]. Pathol Biol (Paris) 1994; 42: 491-7. (Pubitemid 24240386)
8. Witte W. Zur MRSA-Situation in Deutschland 2005 und 2006: Situa- tionsbericht aus dem Nationalen Referenzzentrum fur Staphylokokken. Epidemiologisches Bulletin 2007 Feb 9; (6): 41-6 [online]. Available from URL: http://www.rki.de/cln-109/nn-264978/DE/Content/Infekt/EpidBull/Archiv/2007/ 06-07,templateId=raw,property=publicationFile.pdf/06-07.pdf [Accessed 2011 May 31].
9. Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial suscepti- bility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 2010; 35: 497-9.
10. Falagas ME, Kastoris AC, Kapaskelis AM, etal. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum b-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
11. Corti N, Sennhauser FH, Stauffer UG, et al. Fosfomycin in the initial treat- ment of acute haematogenous osteomyelitis. Arch Dis Child 2003; 88: 512-6. (Pubitemid 36648943)
12. Baquero F, Hortelano JG, Navarro M, et al. Antibiotherapy of Serratia marcescens septicemia in children. Chemotherapy 1977; 23 (Suppl. 1): 416-22. (Pubitemid 8015043)
13. Kirby WMM. Pharmacokinetics of fosfomycin. Chemotherapy 1977; 23: 141-51. (Pubitemid 8015947)
14. Frossard M, Joukhadar C, Erovic B, et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Anti-microb Agents Chemother 2000; 44 (10): 2728-32.
15. Joukhadar C,Klein N, DittrichP, etal. Target site penetration of fosfomycinin critically ill patients. J Antimicrob Chemother 2003; 51: 1247-52. (Pubitemid 36622081)
16. Legat FJ, Maier A, Dittrich P, et al. Penetration of fosfomycin into in- flammatory lesions in patients with cellulitis and diabetic foot syndrome. Antimicrob Agents Chemother 2003 Jan; 47 (1): 371-4. (Pubitemid 36070388)
17. Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010; 65: 995-8.
18. Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic- pharmacodynamic indices. Int J Antimicrob Agents 2010; 35: 431-8.
19. Kumon H, Ono N, Iida M, et al. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 1995; 39 (5): 1038-44.
20. Grif K, Dierich MP, Pfaller K, et al. In vitro activity of fosfomycin in combi- nation with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209-17. (Pubitemid 32755281)
21. Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004; 53: 848-52. (Pubitemid 38660290)
22. Zeitlinger MA, Marsik C, Georgopoulos A, et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. Int J Antimicrob Agents 2003; 21: 562-7. (Pubitemid 36668010)
23. Frere JM. Proceedings: the molecular mechanism of action of beta-lactam antibacterials: the solution of an apparent paradox. Arch Int Physiol Biochim 1975; 83: 184-6.
24. Craig WA. Interrelationship between pharmacokinetics and pharmaco- dynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
25. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibac- terials in the intensive care unit: setting appropriate dosage regimens. Int J Antimicrob Agents 2008; 32: 294-301.
26. LLorens J, Ley G, Fores A, et al. Acute infantile pneumonopathies treated with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 315-23. (Pubitemid 8015028)
27. Aoyagi S, Kawara T, Mizoguchi T, et al. Methicillin-resistant Staphylococcus aureus endocarditis following patch closure of a ventricular septal defect: report of a case. Jpn J Surg 1994; 24: 644-7. (Pubitemid 24229315)
28. Infectopharm Arzneimittel und Consilium GmbH. Infectofos™ 2g/3g/5g/8g: summary of product characteristics [in German]. Heppenheim: Infectopharm Arzneimittel und Consilium GmbH, 2009 Jun.
29. Laboratorios Busto. Solufos™ intravenoso 4g 1 inyectable: summary of pro- duct characteristics [in Spanish; online]. Available from URL: http://prospec.tos.org/prospectos/solufos-intravenoso-4g-1-inyectable/ [Accessed 2011 May 5].
30. Sanofi-Aventis France. Fosfocine™ 4g IV, poudre et solution preparation in- jectable pour perfusion: summary of product characteristics [in French; online]. Available from URL: http://www.therapeutique.info/rcp.php?code= 4342 [Accessed 2011 May 5].
31. Iwai N, Nakamura H, Miyazu M, et al. A study of the absorption and excretion of fosfomycin in children. Jpn J Antibiot 1991 Mar; 44 (3): 345-56.
32. Guggenbichler JP, Kienel G, Frisch H. Fosfomycin, ein neues Antibiotikum. Padiatr Padol 1978; 13: 429-36.
33. Molina MA, Olay T, Quero J. Pharmacodynamic data on fosfomycin in under- weight infants during the neonatal period. Chemotherapy 1977; 23 (Suppl. 1): 217-22. (Pubitemid 8015958)
34. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data anal- ysis: concepts and applications. 3rd ed. Stockholm: Apotekarsocieteten, 2000.
35. Goto S. Fosfomycin, antimicrobial activity in vitro and in vivo. Chemotherapy 1977; 23 Suppl. 1: 63-74. (Pubitemid 8015935)
36. Toutain PL, Bousquet-Melou A. Plasma terminal half-life. J Vet Pharmacol Ther 2004; 27: 427-39. (Pubitemid 39665130)
37. Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005 Oct; 49 (10): 4210-9. (Pubitemid 41400966)
38. Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin- resistant enterococci. J Antimicrob Chemother 1999; 43: 211-7. (Pubitemid 29082445)
39. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 497-513.
40. Alcorn J,McNamara PJ. Pharmacokinetics inthe newborn. Adv Drug Del Rev 2003; 55: 667-86.
41. Galaske RG. Renal functional maturation: renal handling of proteins by ma- ture and immature newborns. Eur J Pediatr 1986; 145: 368-71. (Pubitemid 17042459)
42. Atiyeh BA, Dabbagh SS, Gruskin AB. Evaluation of renal function during childhood. Pediatr Rev 1996; 17: 175-80.
43. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function matura- tion: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
44. Olavarria F, Dolz H, Krause S, et al. Influence of gestational age and postnatal kidney maturation on the kinetics of gentamicin. Rev Chil Pediatr 1990 Mar-Apr; 61 (2): 86-90.
45. American Academy of Pediatrics. Policy statement: age terminology during the neonatal period. Pediatrics 2004; 114: 1362-4.
46. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints [online]. Available from URL: http://www.eucast.org/clinical- breakpoints/ [Accessed 2011 May 4].
47. Members ofthe SFM Antibiogram Committee. Comite del'Antibiogramme de la Societe Française de Microbiologie report 2003. Int J Antimicrob Agents 2003; 21: 364-91.
48. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement [document reference M100-S18; online]. Available from URL: http://www. clsi.org [Accessed 2011 Apr 4].
49. Suzuki S, Murayama Y, Sugiyama E, et al. Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function. Yakugaku Zhassi 2009; 129 (7): 829-42.
50. Fernandez Lastra C, Marino EL, Dominguez-Gil A, et al. The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid. Eur J Clin Pharmacol 1983; 25: 333-8. (Pubitemid 13005578)
51. Al-Dahhan J, Haycock GB, Chantler C, et al. Sodium homeostasis in term and preterm neonates. Arch Dis Child 1983; 58: 335-42 (Pubitemid 13091344)